Financial

Hello Heart Appoints Bill Otten as Commercial President

MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the digital leader in preventive heart health, today announced the appointment of healthcare industry veteran Bill Otten as Commercial President, reporting into Maayan Cohen, CEO and co-founder. He joins the company following another recent key hire, renowned cardiologist Jayne Morgan, MD who joined as VP, Medical Affairs. Together […]

Heart Repair Technologies, Inc. Appoints David H. Chung as Chief Executive Officer

SAN JOSE, Calif.–(BUSINESS WIRE)–Heart Repair Technologies, Inc. (“HRT” or “Company”), a privately-held medical device company specializing in disruptive mitral and tricuspid valve repair technology to resolve heart valve regurgitation in heart failure patients, today announced that David H. Chung has been appointed Chief Executive Officer (CEO), effective as of October […]

Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses

October 28, 2024 (DENVER) – Cleerly, a pioneer in advanced cardiovascular imaging, is thrilled to announce that the American Medical Association (AMA) has approved a CPT Category I code for its AI-QCT advanced plaque analyses. This significant milestone, set to take effect January 1, 2026, marks a transformative step in […]

Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024

ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

Los Angeles, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced its successful appeal to the NASDAQ Panel, and as a result the Company’s common stock will resume trading on the NASDAQ Capital Market Exchange at the open of trading on Wednesday, October 23, 2024. The Company was granted an extension until March 7, 2025, a 360-day grace period from the point at which the Market Value of Listed Securities (“MVLS”) requirement previously became non-compliant.